Treace Medical Concepts, Inc

Treace Medical Concepts, Inc(TMCI)の株式分析

$4.650

+0.051 (+1.09%)終値時点

Loading chart…
High
4.785
Open
4.650
VWAP
4.66
Vol
237.10K
Mkt Cap
411.73M
Low
4.550
Amount
1.11M
EV/EBITDA, TTM
-5.56

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.

AI analysis of Treace Medical Concepts, Inc (TMCI)

buy

Treace Medical Concepts Inc (TMCI) is a good buy right now at a current price of $4.65, especially considering its recent price momentum with a 5-day change of +7.14% and a year-to-date change of +86.00%. The stock's RSI is at 54.404, indicating it is neither overbought nor oversold, which suggests potential for further upside. However, the main risk is the negative earnings trend, with a reported EPS of -0.24 for Q2 2026, which reflects ongoing losses.

バリュエーション指標

The current forward P/E ratio for Treace Medical Concepts, Inc (TMCI) is 0.00, compared to its 5-year average forward P/E of -24.56.

Forward P/E

Fair
5Y Average P/E
-24.56
Current P/E
0.00
割高
1.18
割安
-50.29

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
50.43
Current EV/EBITDA
-5.56
割高
519.90
割安
-419.04

Forward P/S

Fair
5Y Average P/S
4.36
Current P/S
1.35
割高
7.52
割安
1.21

Alphio AI Price Scenarios for TMCI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TMCI

$6.51

シナリオ価格

B

Base

Base · 50%TMCI

$5.93

シナリオ価格

B

Bear

Bear · 25%TMCI

$4.95

シナリオ価格

Whales holding TMCI

A

Armistice Capital LLC

+ HoldingTMCI

+13.92%

3M Return

イベントタイムライン

2026-08-07 (ET)

07:30:00

Company Raises 2026 Revenue Guidance to $204M-$212M

07:30:00

Treace Medical Reports Q2 Revenue of $45.38M

2026-06-18 (ET)

07:30:00

Treace Medical Successfully Completes First HyperPlate XM Implant Case

2026-05-08 (ET)

07:20:00

Treace Medical Reports Q1 Revenue of $47.2M

07:20:00

Treace Expects FY26 Adjusted EBITDA of $4M-$6M

ニュース

TMCI FAQ — answered by Alphio AI

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Treace Medical Concepts Inc (TMCI) is a good buy right now at a current price of $4.65, especially considering its recent price momentum with a 5-day change of +7.14% and a year-to-date change of +86.00%. The stock's RSI is at 54.404, indicating it is neither overbought nor oversold, which suggests potential for further upside. However, the main risk is the negative earnings trend, with a reported EPS of -0.24 for Q2 2026, which reflects ongoing losses.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める